Oral Semaglutide Mechanism

Oral semaglutide (Rybelsus) represents the first approved oral glucagon-like peptide-1 (GLP-1) receptor agonist, achieving clinically meaningful glycemic control and weight reduction without parenteral administration. The formulation relies on the absorption enhancer sodium N-(8-[2-hydroxybenzoyl]amino) caprylate (SNAC) to overcome the formidable barriers to oral peptide delivery: enzymatic degradation, poor mucosal permeation, and hepatic first-pass metabolism.

SNAC Absorption Enhancer

SNAC functions as a locally concentrated absorption enhancer within the gastric environment. At the high molar excess used in the formulation (300 mg SNAC versus 3 mg semaglutide), SNAC raises local pH through buffering activity, reducing pepsin-mediated proteolytic degradation. Additionally, SNAC promotes transient widening of paracellular tight junctions and increases membrane fluidity, facilitating transcellular passive diffusion of semaglutide across gastric epithelial cells.

Gastric Protection Mechanism

The formulation creates a microenvironment where semaglutide is protected from enzymatic degradation. SNAC-induced local pH elevation reduces pepsin activity by approximately 60-80% in the immediate vicinity of the dissolving tablet. This localized protection permits sufficient intact peptide to survive gastric transit and reach the absorptive epithelium. Formulation studies demonstrate that SNAC reduces semaglutide degradation rates by 5-10 fold in simulated gastric fluid.

Transcellular Absorption

Contrary to initial assumptions, oral semaglutide absorption occurs primarily in the stomach rather than the small intestine. The peptide crosses gastric epithelial cells via transcellular passive diffusion, a process enhanced by SNAC-mediated changes in membrane lipid organization. Biodistribution studies confirm gastric absorption accounting for approximately 80% of systemic drug exposure. The absorption window occurs within 30-60 minutes of dosing, coinciding with tablet dissolution.

Oral Bioavailability

Despite these formulation advances, oral semaglutide achieves only approximately 0.4-1.0% absolute oral bioavailability compared to subcutaneous administration. This low efficiency necessitates the relatively high oral dose (7-14 mg) compared to the subcutaneous dose (0.25-1.0 mg weekly). However, the convenience advantage drives significant patient preference and improved medication adherence, translating to comparable clinical outcomes in HbA1c reduction and weight management.